B. Riley reaffirmed their buy rating on shares of AVEO Pharmaceuticals (NASDAQ:AVEO) in a report released on Tuesday morning. The brokerage currently has a $5.00 price objective on the biopharmaceutical company’s stock.
A number of other analysts have also weighed in on the company. Seaport Global Securities reaffirmed a buy rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research lowered AVEO Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, December 6th. assumed coverage on shares of AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a buy rating and a $5.00 target price for the company. Finally, BidaskClub downgraded shares of AVEO Pharmaceuticals from a sell rating to a strong sell rating in a research note on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. AVEO Pharmaceuticals currently has an average rating of Hold and an average target price of $4.05.
AVEO Pharmaceuticals (NASDAQ AVEO) traded down $0.02 during trading on Tuesday, hitting $2.82. The stock had a trading volume of 1,372,880 shares, compared to its average volume of 1,540,000. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. The stock has a market capitalization of $333.63, a price-to-earnings ratio of -3.97 and a beta of 1.14.
Several hedge funds have recently modified their holdings of AVEO. Vanguard Group Inc. grew its stake in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock worth $7,884,000 after purchasing an additional 1,162,232 shares in the last quarter. EAM Investors LLC acquired a new position in shares of AVEO Pharmaceuticals during the second quarter worth $1,979,000. Fore Research & Management LP acquired a new position in shares of AVEO Pharmaceuticals during the second quarter worth $111,000. RA Capital Management LLC acquired a new position in shares of AVEO Pharmaceuticals during the second quarter worth $18,727,000. Finally, Rehmann Capital Advisory Group acquired a new position in AVEO Pharmaceuticals in the third quarter valued at $193,000. Hedge funds and other institutional investors own 50.91% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/17/aveo-pharmaceuticals-aveo-buy-rating-reiterated-at-b-riley.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.